PregLem, a Geneva, Switzerland-based developer of therapeutic compounds for female reproductive medicine, has raised CHF 36 million ($32m) in Series B funding. Sofinnova Ventures led the round, and was joined by return backers Sofinnova Partners, MVM Life Science Partners and NeoMed Management. The funds will be used to developer a molecule licensed-in from HRA Pharma (France), for the pre-operative treatment of uterine myoma. PregLem has now raised a total of CHF 68 million.
PregLem, a Swiss specialty biopharmaceutical company focused on the development and commercialization of innovative therapeutic compounds for female reproductive medicine, today announced the closing of a CHF 36 million Series B financing round (